SCHEDULE 13G/A: BlackRock Discloses 1.9% Passive Stake in Ovid Therapeutics
Beneficial Ownership Disclosure
BlackRock, Inc. has reported a 1.9% beneficial ownership stake in Ovid Therapeutics Inc., holding 1,369,010 shares of common stock as of June 30, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G, disclosing its beneficial ownership in Ovid Therapeutics Inc.
- BlackRock holds an aggregate of 1,369,010 shares of Ovid Therapeutics Inc. common stock.
- This ownership represents 1.9% of the total outstanding common stock of Ovid Therapeutics Inc.
- BlackRock maintains sole voting power over 1,359,560 shares and sole dispositive power over 1,369,010 shares.
- The securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of Ovid Therapeutics Inc.
- The filing date for this statement is July 17, 2025, with the event date requiring the filing being June 30, 2025.
- BlackRock's reporting business units involved include BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, and BlackRock Investment Management, LLC.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing a passive ownership stake, providing no inherently positive or negative operational or financial news for the issuer.
Future Outlook
The filing indicates BlackRock's intent to hold the securities in the ordinary course of business, not for the purpose of changing or influencing control of Ovid Therapeutics Inc.
Management Comments
- "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing represents a routine disclosure by a major institutional investor, BlackRock, Inc., regarding its passive ownership stake in Ovid Therapeutics Inc. It does not provide specific insights into Ovid Therapeutics' operational performance or broader industry trends, but rather reflects BlackRock's portfolio management activities.
Stakeholder Impact
- Minimal direct impact on shareholders as it is a passive investment disclosure.
- No direct impact on employees, customers, suppliers, or creditors of Ovid Therapeutics Inc. is mentioned.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney for BlackRock, Inc. was revoked. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-06-30 | Date of event which required the filing of this statement. |
| 2025-07-17 | Filing date of Schedule 13G Amendment No. 1. |
Keywords
Ovid Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Pharmaceutical, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.